Enveric Biosciences, Inc.
ENVB
$1.69
$0.095.63%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.87% | 24.53% | |||
| Depreciation & Amortization | -5.82% | -2.23% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.56% | 17.08% | |||
| Operating Income | 25.56% | -17.08% | |||
| Income Before Tax | 25.55% | -17.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.55% | -17.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.55% | -17.11% | |||
| EBIT | 25.56% | -17.08% | |||
| EBITDA | 25.92% | -17.50% | |||
| EPS Basic | 82.34% | 43.36% | |||
| Normalized Basic EPS | 67.49% | 44.39% | |||
| EPS Diluted | 82.34% | 43.36% | |||
| Normalized Diluted EPS | 67.49% | 44.39% | |||
| Average Basic Shares Outstanding | 128.95% | 110.63% | |||
| Average Diluted Shares Outstanding | 128.95% | 110.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||